Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst
1. PODD Q4 adjusted EPS was $1.15, beating the $1.02 consensus. EPS declined from $1.40 a year ago. 2. Q4 sales reached $597.5M, exceeding consensus estimates and guidance. Revenue growth was robust. 3. International Omnipod revenue surged by 33%, compared to a moderate 12.4% U.S. gain. Performance varied by region. 4. 2025 guidance projects 16%-20% revenue growth with strong Omnipod sales. Analysts remain optimistic about growth catalysts.